<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="36" ids="36916">Cation</z:chebi> channels conduct calcium, <z:chebi fb="199" ids="26708">sodium</z:chebi>, and <z:chebi fb="120" ids="26216">potassium</z:chebi>, <z:chebi fb="36" ids="36916">cations</z:chebi> that are likely deleterious in the evolution of focal ischemic injury </plain></SENT>
<SENT sid="1" pm="."><plain>Diffusion-weighted magnetic resonance imaging (DWI) is a powerful tool for evaluation of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the effects of a novel, broad-spectrum inhibitor of several <z:chebi fb="36" ids="36916">cation</z:chebi> channels, LOE 908 MS, on <z:hpo ids='HP_0011009'>acute</z:hpo> ischemic lesion development with DWI and on cerebral <z:mpath ids='MPATH_124'>infarct</z:mpath> size using 2,3,5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) staining postmortem </plain></SENT>
<SENT sid="3" pm="."><plain>Eighteen male Sprague-Dawley rats underwent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) and were randomly and blindly assigned to either LOE 908 MS (1 mg/kg bolus 30 min after MCAO and continuous i.v. infusion of 10 mg/kg for 4 h thereafter) or vehicle </plain></SENT>
<SENT sid="4" pm="."><plain>Whole-brain DWI was done before initiation of treatment and repeated every 30 min for the next 3.5 h </plain></SENT>
<SENT sid="5" pm="."><plain>The animals were reperfused in the magnetic resonance imaging (MRI) scanner 90 min after MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>At 24 h, the animals were killed, and the brains were cut into six 2-mm-thick slices and stained with 2% TTC </plain></SENT>
<SENT sid="7" pm="."><plain>Percent hemispheric lesion volume (%HLV) was calculated for each animal </plain></SENT>
<SENT sid="8" pm="."><plain>Physiological parameters, body weight, and premature mortality (3 in the placebo group and 1 in the treated group) did not differ between the groups </plain></SENT>
<SENT sid="9" pm="."><plain>No <z:hpo ids='HP_0002615'>hypotension</z:hpo>, <z:mp ids='MP_0004924'>abnormal behavior</z:mp>, or other adverse effects were seen </plain></SENT>
<SENT sid="10" pm="."><plain>Pretreatment, the DWI-derived %HLV did not differ between the groups (19.8 +/- 6.2 in the control group and 17.9 +/- 7.9 in the treated group), whereas at 4 h after MCAO, it was significantly smaller in the treated group (21.8 +/- 15.4 vs 40.4 +/- 15.5, p = 0.03) </plain></SENT>
<SENT sid="11" pm="."><plain>Postmortem, TTC-derived %HLV was significantly attenuated in the LOE 908 MS group (21.3 +/- 11.9 vs 50.1 +/- 10.7, p = 0.0001) and the neurological scores at 24 h were significantly better among the treated rats (2.1 +/- 1.5 vs 4.0 +/- 1.0, p &lt; 0.02) </plain></SENT>
<SENT sid="12" pm="."><plain>LOE 908 MS significantly improved neurological outcome and reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size without observable effects in rats as demonstrated in vivo by DWI and confirmed postmortem by TTC staining </plain></SENT>
<SENT sid="13" pm="."><plain>Blocking several distinct <z:chebi fb="36" ids="36916">cation</z:chebi> channels by LOE 908 MS showed significant neuroprotection </plain></SENT>
</text></document>